Login
MannKind Corporation NASDAQ: MNKD
MannKind Corporation is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases, such as diabetes
| Name | MannKind Corporation |
| Ticker | MNKD |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Diabetes |
|
Price
52W Low/High |
4.30
1.19 / 6.14 |
| Momentum | Weak Up |
| Market cap | 1.0 B |
| 1Y Total Return |
252.46%
Strong |
| 1Y Volatility |
90.30%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
MannKind Corporation is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases, such as diabetes
Details
| Ticker | MNKD |
| Name | MannKind Corporation |
| ISIN | |
| CUSIP | 56400P201 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Diabetes |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 4/15/21
| Close Price | 4.30 |
| 52W Low/High | 1.19 / 6.14 |
| Market cap | 1.0 B |
| 1Y Total Return |
252.46%
Strong |
| 1Y Volatility |
90.30%
High Risk |
| Beta | 2.51 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -87.9% |
| Cash from Op. / Cur. Liabilities | -0.38 |
| Diluted Earnings / Share | -0.26 |
| ROE | - |
| ROIC | - |
| Price / Revenue | 14.7 |
| Price / Book | -5.3 |
| Price / CF | -34.0 |
| Current Ratio | 1.1 |
| Cur.Liabilities / Tot.Liabilities | 0.3 |
| Financial Leverage | - |
| in Mils USD |
rolling-year up to December
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
65
|
63
|
28
|
12
|
175
|
0
|
|
| Gross Profit |
41
|
35
|
7
|
-
|
125
|
-
|
|
| R&D |
6
|
7
|
9
|
14
|
15
|
30
|
|
| EBITDA |
-45
|
-39
|
-74
|
-100
|
148
|
-331
|
|
| Operating Income |
-40
|
-47
|
-81
|
-95
|
64
|
-342
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
126
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
223
|
196
|
144
|
104
|
92
|
81
|
|
| EPS exc. Extra |
-0.26
|
-0.27
|
-0.60
|
-1.13
|
1.36
|
-4.54
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
109
|
94
|
108
|
85
|
107
|
126
|
|
| Cash, Eq & Invt ShortTerm |
67
|
50
|
72
|
48
|
23
|
59
|
|
| Total Current Assets |
79
|
61
|
82
|
57
|
77
|
77
|
|
| Total Non-Current Assets |
29
|
33
|
26
|
27
|
30
|
50
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
289
|
284
|
283
|
299
|
291
|
477
|
|
| Total Current Liabilities |
74
|
66
|
75
|
88
|
92
|
268
|
|
| Long Term Debt |
215
|
219
|
208
|
212
|
199
|
208
|
|
| Shareholder equity |
-180
|
-191
|
-175
|
-215
|
-184
|
-350
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-28
|
-88
|
-38
|
-65
|
-78
|
-57
|
|
| Depreciation |
3
|
2
|
3
|
4
|
4
|
13
|
|
| Cash from Investing |
15
|
-23
|
0
|
17
|
-1
|
-10
|
|
| Capex |
1
|
3
|
0
|
0
|
1
|
10
|
|
| Cash from Financing |
50
|
70
|
61
|
74
|
43
|
6
|
|
| Stock Issued |
35
|
9
|
70
|
62
|
51
|
79
|
|
| Debt (LT) Issued |
15
|
63
|
-5
|
15
|
-5
|
-65
|
|
| Free Cash Flow |
-39
|
-58
|
-93
|
-57
|
-85
|
-416
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
71.9%
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-122.3%
|
-
|
|
| Current Ratio |
1.1
|
0.9
|
1.1
|
0.7
|
0.8
|
0.3
|
|
| Financial Leverage D/E |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Return on Capital Avg |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available